Arrowhead Reports Interim Phase 1/2a Data for ARO-MAPT

Arrowhead Pharmaceuticals announced interim results from an ongoing Phase 1/2a study of its investigational RNAi therapy ARO-MAPT, reporting deep and durable tau reductions in healthy volunteers.